Biocross S.L., a biotechnology company focused on the development of innovative technologies for the diagnosis of Alzheimer’s disease and the identification of at-risk individuals, today announced that their Chief Executive Officer Matt Mittino will present the company’s projects at BIO-Europe 2016, the 22nd Annual International Partnering Conference, to be held Cologne, Germany from November 7–9, 2016.
Biocross is seeking commercial partners interested in licensing or acquiring the test, and aims to acquire international financing to complete the ApoE4 blood marker assay and proceed with the development of the AD Dementia test, which will include a new clinical study.
BIO-Europe 2016 is Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma, and finance along with the most exciting emerging companies.
Date/Time: 9 a.m, Thursday, November X, 2016.
Location: KoelnMesse – Congress Center North, Cologne, Germany.